NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)

9 Months Ended

Sep. 30, 2025

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

		Fair Value		Level 1		Level 2		Level 3
Fair Value at December 31, 2023	$		154,150		-		-	$	154,150
Derivative liability			471,270		-		-		471,270
Fair Value at December 31, 2024	$		625,420		-		-	$	625,420
Derivative liability			67,423		-		-		67,423
Fair Value at September 30, 2025	$		557,997		-		-	$	557,997

September 30, 2025

		Level 1				Level 2				Level 3				Total
Derivative liability			-				-				557,997			$	557,997

December 31, 2024

		Level 1				Level 2				Level 3				Total
Derivative liability			-				-				625,420			$	625,420

The details of derivative liability transactions for the nine months ended September 30, 2025 and the year ended December 31, 2024 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2023		$154,150
Issued during the year ended December 31, 2024		-
Derivative liabilities debt premium		-
Change in fair value recognized in operations		471,270
Converted during the year ended December 31, 2024		-
Balance, December 31, 2024		$625,420
Issued during the nine months ended September 30, 2025		-
Derivative liabilities debt discount		-
Change in fair value recognized in operations		20,679
Converted during the nine months ended September 30, 2025		(88,102)
Balance, September 30, 2025		$557,997

HEALTHY EXTRACTS INC. 10-Q